Frontier Medicines

Frontier Medicines is revolutionizing the field of precision medicine with its innovative approach to developing cancer therapies. By integrating chemoproteomics, covalent drug discovery, and machine learning into their proprietary platform, Frontier Medicines is unlocking new possibilities in therapeutic treatments, particularly for proteins once deemed undruggable. This groundbreaking work is not only expanding the realm of druggable targets but also accelerating the pace of drug discovery and development, offering new hope for patients with genetically-defined cancers.

The company's lead program, FMC-376, targets KRAS G12C mutations found in a significant portion of non-small cell lung cancer cases, as well as colorectal and pancreatic cancers. This focus on precision medicine ensures that therapies can be more effectively tailored to individual patient needs, promising better outcomes for those with difficult-to-treat cancers.

Frontier Medicines' breakthroughs are not only beneficial for patients but also for oncologists and research scientists, who gain new tools and methodologies to combat and explore various fields of medical research.